DGAP-News: Evotec and Dow AgroSciences announce collaboration on Cellular Target Profiling
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec and Dow AgroSciences announce collaboration on Cellular Target
Profiling
09.07.2013 / 07:29
---------------------------------------------------------------------
Hamburg, Germany - 09 July 2013: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced that Evotec and Dow
AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE:
DOW), have entered into a research collaboration with the objective of
leveraging Evotec's advanced chemical proteomics services to support
compounds in development at Dow AgroSciences. To this end, Evotec will
perform quantitative chemical proteomics services (Cellular Target
Profiling) to de-convolute phenotypic screening results obtained by Dow.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We look
forward to working with Dow AgroSciences on this project. This
collaboration highlights the broad applicability of Evotec's industry
leading chemical proteomics platform to determine cellular target
affinities and mechanisms of action on a proteome wide level and in a
native context.'
Dr William Kleschick, Discovery Global Leader of Dow AgroSciences, added:
'Dow AgroSciences is pleased to announce this new partnership with Evotec,
an innovative leader in advanced chemical proteomics. This collaboration
enhances Discovery's technology tool-box to accelerate our efforts to
deliver novel solutions to our customers around the world.'
No financial details are disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
ABOUT DOW AGROSCIENCES
Dow AgroSciences, based in Indianapolis, Indiana, USA, develops
leading-edge crop protection and plant biotechnology solutions to meet the
challenges of the growing world. Dow AgroSciences is a wholly owned
subsidiary of The Dow Chemical Company and had annual global sales of $6.4
billion in 2012. Learn more at www.dowagro.com. Follow Dow AgroSciences on
Facebook and YouTube or subscribe to our News Release RSS Feed.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
09.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
220325 09.07.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2013 - 07:29 Uhr
Sprache: Deutsch
News-ID 276431
Anzahl Zeichen: 7287
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec and Dow AgroSciences announce collaboration on Cellular Target Profiling"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
